Roivant Sciences Ltd. ROIV
General analysis — not personal advice.
The combination of improved liquidity outlook via the Moderna payment, clearer pipeline timelines, and reprioritization from batoclimab to IMVT-1402 improves the risk/reward into 2H 2026 readouts.
This picture changes. Follow Roivant Sciences Ltd. free — email when the signal or risk changes + a Sunday weekly brief.
Follow Roivant Sciences Ltd. freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Price & valuation
Market sentiment
Why BUY?
- ADD in tranches ahead of the July payment and 2H 2026 readouts; keep position sizing disciplined due to binary clinical outcomes and monitor any signals of financing/dilution.
Recent News
- Since 2026-06-07, no new company-specific press releases have been noted. The stock reached new 52-week highs in late June 2026 (~$34.7–$35.9) and has traded around $34–$35.5 in early July with intermittently elevated volume. There have also been reports of insider selling/Form 144 activity and some ownership changes (e.g., stake reductions and an updated 13G/A), but no new operational/clinical data have been communicated.
Dilution Risk
Assessment: Medium
What Firelda Watch includes for Roivant Sciences Ltd.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — AI roundup of the week's news
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Own Roivant Sciences Ltd.? Create a free account and follow up to 3 companies — change history, weekly brief, and email when the picture changes. Upgrade to Watch for more slots and same-day alerts.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more